These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17646074)

  • 1. Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy.
    Noren B; Dahlqvist O; Lundberg P; Almer S; Kechagias S; Ekstedt M; Franzén L; Wirell S; Smedby O
    Eur J Radiol; 2008 May; 66(2):313-20. PubMed ID: 17646074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The relationship between 31P magnetic resonance spectroscopy and the histopathology of livers of chronic viral hepatitis patients].
    Wu B; Song B; Zhou XP; Yang Y; Lei XZ; Jiang LL
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):338-41. PubMed ID: 17524264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C.
    Lim AK; Patel N; Hamilton G; Hajnal JV; Goldin RD; Taylor-Robinson SD
    Hepatology; 2003 Apr; 37(4):788-94. PubMed ID: 12668971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances.
    Menon DK; Sargentoni J; Taylor-Robinson SD; Bell JD; Cox IJ; Bryant DJ; Coutts GA; Rolles K; Burroughs AK; Morgan MY
    Hepatology; 1995 Feb; 21(2):417-27. PubMed ID: 7843715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling.
    Sevastianova K; Hakkarainen A; Kotronen A; Cornér A; Arkkila P; Arola J; Westerbacka J; Bergholm R; Lundbom J; Lundbom N; Yki-Järvinen H
    Radiology; 2010 Aug; 256(2):466-73. PubMed ID: 20656836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.
    Kaneda H; Hashimoto E; Yatsuji S; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1459-65. PubMed ID: 16911693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis.
    Miyaaki H; Ichikawa T; Nakao K; Yatsuhashi H; Furukawa R; Ohba K; Omagari K; Kusumoto Y; Yanagi K; Inoue O; Kinoshita N; Ishibashi H; Yano M; Eguchi K
    Liver Int; 2008 Apr; 28(4):519-24. PubMed ID: 17976158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease: spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study.
    Abrigo JM; Shen J; Wong VW; Yeung DK; Wong GL; Chim AM; Chan AW; Choi PC; Chan FK; Chan HL; Chu WC
    J Hepatol; 2014 Apr; 60(4):809-15. PubMed ID: 24291241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.
    Tahan V; Canbakan B; Balci H; Dane F; Akin H; Can G; Hatemi I; Olgac V; Sonsuz A; Ozbay G; Yurdakul I; Senturk H
    Hepatogastroenterology; 2008; 55(85):1433-8. PubMed ID: 18795706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of 31P magnetic resonance spectroscopy and microbubble-enhanced ultrasound for characterizing hepatitis c-related liver disease.
    Lim AK; Patel N; Eckersley RJ; Fitzpatrick J; Crossey MM; Hamilton G; Goldin RD; Thomas HC; Vennart W; Cosgrove DO; Taylor-Robinson SD
    J Viral Hepat; 2011 Oct; 18(10):e530-4. PubMed ID: 21914073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C.
    Dinesen L; Caspary WF; Chapman RW; Dietrich CF; Sarrazin C; Braden B
    Dig Liver Dis; 2008 Sep; 40(9):743-8. PubMed ID: 18339592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer disease.
    Gonzalez RG; Guimaraes AR; Moore GJ; Crawley A; Cupples LA; Growdon JH
    Alzheimer Dis Assoc Disord; 1996; 10(1):46-52. PubMed ID: 8919496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus.
    Tural C; Tor J; Sanvisens A; Pérez-Alvarez N; Martínez E; Ojanguren I; García-Samaniego J; Rockstroh J; Barluenga E; Muga R; Planas R; Sirera G; Rey-Joly C; Clotet B
    Clin Gastroenterol Hepatol; 2009 Mar; 7(3):339-45. PubMed ID: 19171202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection.
    Sanvisens A; Serra I; Tural C; Tor J; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Muga R
    J Viral Hepat; 2009 Jul; 16(7):513-8. PubMed ID: 19200132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered.
    McPherson S; Jonsson JR; Cowin GJ; O'Rourke P; Clouston AD; Volp A; Horsfall L; Jothimani D; Fawcett J; Galloway GJ; Benson M; Powell EE
    J Hepatol; 2009 Aug; 51(2):389-97. PubMed ID: 19505740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
    Alric L; Kamar N; Bonnet D; Danjoux M; Abravanel F; Lauwers-Cances V; Rostaing L
    Transpl Int; 2009 May; 22(5):568-73. PubMed ID: 19196449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 31P magnetic resonance spectroscopy of the liver: correlation with standardized serum, clinical, and histological changes in diffuse liver disease.
    van Wassenaer-van Hall HN; van der Grond J; van Hattum J; Kooijman C; Hoogenraad TU; Mali WP
    Hepatology; 1995 Feb; 21(2):443-9. PubMed ID: 7843719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
    Ekstedt M; Franzén LE; Holmqvist M; Bendtsen P; Mathiesen UL; Bodemar G; Kechagias S
    Scand J Gastroenterol; 2009; 44(3):366-74. PubMed ID: 19016382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?
    Cheung RC; Currie S; Shen H; Bini EJ; Ho SB; Anand BS; Hu KQ; Wright TL; Morgan TR;
    J Clin Gastroenterol; 2008 Aug; 42(7):827-34. PubMed ID: 18285716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests.
    Nguyen-Khac E; Chatelain D; Tramier B; Decrombecque C; Robert B; Joly JP; Brevet M; Grignon P; Lion S; Le Page L; Dupas JL
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1188-98. PubMed ID: 18705692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.